Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
EDP-239, a new NS5A inhibitor hepatitis C treatment from Enanta, showed promise in a small single-dose monotherapy study.
Those coinfected with HIV and genotype 3 of hepatitis C responded about the same to interferon and ribavirin as those with only hep C in a tri...
Adding BMS-790052, an experimental hepatitis C drug being developed by Bristol-Myers Squibb, to pegylated interferon and ribavirin...
Even a partial response to hepatitis C virus (HCV) therapy confers significant health benefits to people coinfected with both HIV and HCV, tho...
People who switched from a protease inhibitor (PI) to Isentress (raltegravir) did well regardless of whether they switched to a once-daily o...
Tobacco and alcohol interact negatively with efavirenz (found in Sustiva and Atripla) in people who are genetically predisposed to clear efa...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.